Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70years)-Reference-Cited by-同舟云学术

Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70years)

Published:2013-10 Issue:4 Volume:4 Page:340-345
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Basso Umberto,Roma Anna,Brunello Antonella,Falci Cristina,Fiduccia Pasquale,Banzato Alberto,Bononi Antonio,Gusella Milena,Vamvakas Lampros,Zagonel Vittorina,Monfardini Silvio

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference26 articles.

1. Chemotherapy and targeted agents for elderly women with advanced breast cancer;Brunello;Recent Pat Anticancer Drug Discov,2008

2. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA);Biganzoli;Lancet Oncol,2012

3. Management of primary and advanced breast cancer in older unfit patients (medical treatment);Aapro;Cancer Treat Rev,2009

4. Optimizing the use of anthracyclines in older patients with breast cancer;Morris;Crit Rev Oncol Hematol,2001

5. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy;Gabizon;Eur J Pharm Sci,2012

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins;Scientific Reports;2024-03-01

2. A propensity score–weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer;Breast Cancer Research and Treatment;2022-12-23

3. Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis;Diagnostics;2022-11-25

4. Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment;International Journal of Nanomedicine;2021-09

5. Pharmacological cancer treatment and venous thromboembolism risk;European Heart Journal Supplements;2020-04-01